On October 11th, Maryland-based Supernus Pharmaceuticals announced that it is acquiring Adamas Pharmaceuticals in an all-cash deal amounting to approximately $400 million. This roughly comes out to $9.10 per share, which includes an upfront payment of $8.10 per share.

An additional $1.00 contingent value right will be paid if Adamas' top-selling Parkinson's drug, Gocovri, achieves certain sales milestones. Specifically, the first CVR worth $0.50 per share, is payable if net sales touch $150 million in any four consecutive quarters between closing and the end of 2024. The second CVR is payable if the drug makes $225 million in any four consecutive quarters between closing and the end of 2025.